Why visceral fat matters
Visceral fat surrounds internal organs and is different from subcutaneous fat (the fat you can pinch). Excess VAT is associated with higher risks of insulin resistance, dyslipidaemia, fatty liver, hypertension and cardiovascular disease. Reducing VAT is often a goal in people with central adiposity and in specific medical conditions such as HIV‑associated lipodystrophy.
What tesamorelin is and how it targets visceral fat
Tesamorelin is a synthetic analogue of human growth‑hormone releasing hormone (GHRH). It stimulates the pituitary to release growth hormone (GH), which increases insulin‑like growth factor‑1 (IGF‑1). This signalling cascade can influence body composition and has been shown to preferentially reduce visceral adipose tissue in certain populations.
- Mechanism: GHRH analogue → ↑ GH → ↑ IGF‑1 → downstream effects on lipid and fat metabolism
- Target: Greater impact on VAT than on subcutaneous abdominal fat in trials
- Regulatory status: Approved in some countries specifically for HIV‑associated lipodystrophy–related VAT; use outside that context is more limited by evidence
Evidence at a glance: tesamorelin for visceral fat
The strongest evidence for tesamorelin’s VAT reduction comes from randomised controlled trials in adults with HIV‑associated lipodystrophy. Key findings reported across studies include:
- VAT reduction: Average decreases around 10–20% over approximately 26 weeks versus placebo, measured by CT imaging
- Lipid changes: Modest improvements in triglycerides were observed in some trials
- Subcutaneous fat: Little to no meaningful change compared with VAT
- Durability: Continued use helps maintain VAT reduction; stopping often leads to partial re‑accumulation over months
- Glucose effects: A proportion of participants show worsened glucose tolerance or elevated HbA1c, so monitoring is important
For people without HIV, published data are limited. Clinicians generally consider tesamorelin when VAT is a medically significant issue and when evidence‑based alternatives and lifestyle strategies have been addressed.
Discuss study results with a clinician
Related reading: Tesamorelin Benefits, Tesamorelin for HIV Lipodystrophy, Tesamorelin Results Timeline
Who clinicians may consider tesamorelin for
- Adults with HIV‑associated lipodystrophy and excess VAT despite optimised lifestyle management
- People assessed by specialists where VAT is driving significant metabolic risk and where benefits may outweigh risks
Who it’s not typically suitable for:
- General weight loss or cosmetic fat reduction goals without a clear medical indication
- People with contraindications or high risk for adverse effects (see safety section below)
Explore related intent pages: Tesamorelin for Belly Fat, Tesamorelin for Abdominal Obesity, Tesamorelin for Metabolic Syndrome
Safety, side effects and precautions
Like all prescription therapies, tesamorelin has risks and is not suitable for everyone. Discussion with a qualified clinician is essential.
Commonly reported reactions
- Injection‑site reactions (redness, itching, discomfort)
- Fluid retention, swelling, joint or muscle pain
- Tingling or numbness (carpal tunnel‑like symptoms)
- Nausea or gastrointestinal upset
- Raised IGF‑1 levels
Metabolic considerations
- Glucose: Can worsen glucose tolerance or increase HbA1c in some people
- Lipids: Triglycerides may improve in some cases, but monitoring is still recommended
When tesamorelin may be inappropriate
- Active malignancy or a history of malignancy without specialist oversight
- Pregnancy or breastfeeding
- Known hypersensitivity to tesamorelin or formulation components
- Untreated pituitary disease or prior pituitary tumour history without specialist input
Always review your full medical history, current medicines (including glucocorticoids and other agents affecting GH/IGF‑1), and monitoring plan with your prescriber.
Read the Tesamorelin Side Effects guide · Peptide Side Effects overview
Monitoring and follow‑up usually recommended
- Baseline assessment of VAT (clinical exam ± imaging where appropriate)
- IGF‑1 levels, fasting glucose/HbA1c and lipid profile at baseline and periodically
- Symptom review for fluid retention, neuropathy/tingling, or injection‑site issues
- Re‑evaluation at ~3–6 months to judge response and risk–benefit
Access in Australia: what to know
- Prescription‑only: Tesamorelin requires a doctor’s prescription
- Unapproved medicine pathway: Often accessed via the TGA Special Access Scheme (SAS) or an Authorised Prescriber for appropriate indications
- Not an over‑the‑counter product and not legally sold as a “research peptide” for personal use
- Personal importation without proper approvals risks seizure and penalties
- Initiation is typically through relevant specialists (e.g., HIV medicine, endocrinology, metabolic clinics)
Related legal and access guides: Are Peptides Legal in Australia?, Can You Import Peptides Into Australia?, Peptide Clinics Australia, Online Peptide Clinic Australia
Alternatives and complementary approaches
- Lifestyle: Clinically guided nutrition, resistance training, sleep and stress strategies remain foundational for VAT reduction
- GLP‑1/GIP‑based therapies (for eligible patients): GLP‑1 Australia Guide, Wegovy, Mounjaro, Ozempic
- Other GH secretagogues: CJC‑1295, Ipamorelin, Sermorelin — note these are not interchangeable with tesamorelin and have different evidence profiles
Comparisons you might be considering: Tesamorelin vs Sermorelin, Tesamorelin vs Ipamorelin, CJC‑1295 vs Ipamorelin
Key takeaways
- Tesamorelin has the most robust evidence for reducing visceral fat in HIV‑associated lipodystrophy
- Benefits are typically seen over months and may reverse when therapy stops
- Safety monitoring is essential, especially for glucose metabolism and IGF‑1
- In Australia, access requires a prescription and usually proceeds via unapproved medicine pathways for specific indications
Tesamorelin Dosage (what clinicians consider) · Is Tesamorelin Legal in Australia? · How to read Tesamorelin reviews
Frequently asked questions
Does tesamorelin reduce visceral fat?
Yes, trials in HIV‑associated lipodystrophy show average VAT reductions of roughly 10–20% over ~26 weeks compared with placebo. Evidence for people without HIV is limited.
How fast could changes be noticed?
Measurable VAT changes are generally assessed at 3–6 months. Some people notice earlier body‑composition changes, but imaging and labs provide the most objective assessment.
Will fat return after stopping tesamorelin?
VAT commonly re‑accumulates once therapy stops, which is why clinicians re‑assess the need for ongoing treatment versus risks.
Is tesamorelin suitable for general weight loss?
It is not a general weight‑loss medicine. Its strongest evidence is for HIV‑associated lipodystrophy with excess VAT. For broader obesity management, GLP‑1/GIP‑based options may be considered for eligible patients.
How is progress monitored?
Baseline and periodic IGF‑1, fasting glucose/HbA1c, lipid profile, and clinical review for side effects. VAT may be assessed by imaging in specialist settings.
Can I access tesamorelin via telehealth?
Potentially, but it remains prescription‑only and typically uses unapproved medicine pathways. Choose reputable Australian providers and avoid grey‑market sellers.
How does tesamorelin compare with sermorelin or ipamorelin?
They are different molecules with different evidence. Only tesamorelin carries specific approval in some regions for VAT reduction in HIV‑associated lipodystrophy.
Get help with tesamorelin and visceral fat
Send a confidential question. We’ll point you to relevant medical resources and Australian access information. This is not a substitute for personal medical advice.
Prefer to read more first? See Side Effects, Legal Status, or Before and After.